Drug
Aav Rpe65
Aav Rpe65: highest development phase Phase 1/2, developed by MeiraGTx. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- MeiraGTx
Trials
| Drug | Phase | Indication |
|---|---|---|
| AAV RPE65 NCT02781480 | Phase 1/2 | Leber Congenital Amaurosis |
Latest
No recent events.
Follow Aav Rpe65 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.